| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C269-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-205 |
| filingDate |
1996-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1999-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H11501617-A |
| titleOfInvention |
O-carbamoyl- (D) -phenylalaninol and method for producing the same |
| abstract |
(57) Abstract: The present invention provides a compound of the following formula (V) used for treating a central nervous system disease: (In the above formula, R 1 and R 2 may be the same or different, and each independently represents hydrogen, lower alkyl having 1 to 8 carbon atoms, and a nitrogen atom or an oxygen atom which are not bonded to each other. O-carbamoyl- (which is selected from the group consisting of a 5- to 7-membered alicyclic group that may contain up to two and has a total carbon number of R 1 and R 2 of 0 to 16) D) -Phenylalaninol and its pharmaceutically acceptable salts. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8729120-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012531405-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019059764-A |
| priorityDate |
1995-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |